CRYBMIM, a second-generation version of MYBMIM, could specifically target the KIX domain of CREBBP/EP300 with a higher affinity for AML cells but less impact on normal hematopoietic progenitors [136]. Here, EP300 is linked to acute myeloid leukemia.